Table 1.
Clinical characteristics in discovery and validation set
| Group | N | Sex (M/F) | Age | 24 h urine protein (g/L) | Serum creatinine (mg/dL) | CKD stage | Albumin (g/dL) | Cholesterol (mg/dL) |
|---|---|---|---|---|---|---|---|---|
| Discovery set (LC–MS/MS) | ||||||||
| HC | 4 | 4/0 | 30 ± 2 | N/A | N/A | N/A | N/A | N/A |
| MCD | 4 | 1/3 | 49 ± 25 | 9.14 ± 3.6 | 1.2 ± 0.5 | 2.00 ± 0.31 | 2.1 ± 0.3 | 348 ± 88 |
| MN | 4 | 2/2 | 50 ± 16* | 6.56 ± 5.6 | 0.8 ± 0.2 | 1.00 ± 0.00 | 3.9 ± 0.4† | 172 ± 28† |
| FSGS | 4 | 4/0 | 42 ± 23 | 6.17 ± 5.76 | 1.6 ± 0.4 | 2.67 ± 0.33 | 3.9 ± 0.4† | 240 ± 75 |
| Validation set (ELISA) | ||||||||
| HC | 8 | 4/4 | 36 ± 13 | N/A | N/A | N/A | N/A | N/A |
| IgAN | 9 | 4/5 | 50 ± 10* | 1.5 ± 1.1 | 0.98 ± 0.2 | 1.89 ± 0.20 | 4.0 ± 0.3† | 217 ± 33† |
| MCD | 13 | 5/8 | 49 ± 19 | 7.69 ± 3.2‡ | 1.0 ± 0.4 | 2.08 ± 0.18 | 2.5 ± 0.7 | 351 ± 81 |
| MN | 26 | 16/10 | 55 ± 13* | 6.13 ± 3.1‡ | 0.98 ± 0.4 | 1.81 ± 0.15 | 3.2 ± 0.7†,‡ | 239 ± 78† |
| FSGS | 5 | 1/4 | 27 ± 15†, ‡, § | 6.26 ± 5.4‡ | 1.94 ± 0.5†, ‡, § | 2.80 ± 0.20‡, § | 3.8 ± 0.5† | 249 ± 69† |
CKD stage was estimated by MDRD equation
N patients number, HC healthy control, MCD minimal change disease, MN membranous nephropathy, FSGS focal segmental glomerulosclerosis, IgAN IgA nephropathy, N/A not applicable
* p < 0.05 versus HC; † p < 0.05 versus MCD; ‡ p < 0.05 versus IgAN; § p < 0.05 versus MN